Bacterial Infections
Conditions
Brief summary
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Detailed description
In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of last defense for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many hospitals worldwide now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents. Rempex developed meropenem-vaborbactam administered as a fixed combination by IV infusion, to treat serious Gram-negative infections, such as cUTIs, including those infections caused by bacteria resistant to currently available carbapenems. This study is an open label, dose-finding, pharmacokinetics, safety, and tolerability study of a single dose infusion of meropenem-vaborbactam in pediatric subjects from birth to less than 18 years of age with suspected or confirmed bacterial infection receiving antibiotic therapy or subjects receiving peri-operative prophylactic use of antibiotics.
Interventions
DRUGVabomere
Vabomere (meropenem-vaborbactam) for IV injection
Sponsors
Department of Health and Human Services
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
1. A signed and dated written informed consent from the parent or legal representative and a subject assent (according to local IRB requirements); 2. Male or female from birth to \< 18 years of age; 3. Are hospitalized, in stable condition, and receiving systemic antibiotics for a known or suspected bacterial infection; or subjects receiving peri-operative prophylactic use of antibiotics; 4. The subject will be observed in the hospital for at least 6 hours after the study drug is administered; 5. If female and has reached menarche, or has reached Tanner Stage 3 breast development (even if not having reached menarche), the subject is practicing appropriate birth control or is sexually abstinent; 6. Sufficient intravascular access (peripheral or central) to receive study drug. Subjects will be excluded from the study if any of the following
Exclusion criteria
apply prior to randomization: 1. Signs of severe sepsis including: 1. Shock or profound hypotension that is not responsive to fluid challenge; 2. Hypothermia (core temperature \< 35.6 ºC or 96.1 ºF); 3. Disseminated intravascular coagulation as evidenced by prothrombin time or partial thromboplastin time ≥ 2X the ULN or platelets \< 50% of the lower limit of normal; 2. Any surgical or medical condition which, in the opinion of the investigator, would put the subject at increased risk or is likely to interfere with study procedures or PK of the study drug; 3. Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant) during the entire study period; 4. Female adolescent subjects who are pregnant or breastfeeding or have a positive serum β-hCG pregnancy test at screening and at pre-dose Day 1; 5. Males who are unwilling to practice abstinence or use an acceptable method of broth control during the entire study period (i.e. condom with spermicide); 6. Renal function at screening as estimated by creatinine clearance \< 50 mL/min /1.73 m\^2 as calculated using the updated Schwartz bedside formula: eGFR = k x (height in cm) ÷ serum creatinine * k = 0.33 in pre-term infants. * k = 0.45 in term infants to 1 year of age. * k = 0.55 in children and adolescent girls. * k = 0.70 in adolescent boys. 7. Treatment within 30 days prior to enrollment with valproic acid; 8. Treatment within 30 days prior to enrollment with probenecid; 9. Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy; 10. Neutropenia with absolute neutrophil count (ANC) \< 500 cells/mm3; 11. Aspartate aminotransferase or alanine aminotransferase ≥ 3X ULN or total bilirubin ≥ 1.5X ULN; 12. Receipt of any investigational medication or investigational device within 30 days prior to enrollment; 13. Prior exposure to vaborbactam or Vabomere; 14. Use of meropenem within 48 hours of administration of study drug or 12 hours after study drug administration; 15. Known significant hypersensitivity to any beta-lactam antibiotic; 16. Unable or unwilling in the judgment of the Investigator, to comply with the protocol; 17. Subject is a child of an employee of the Investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member of the employee or the Investigator; 18. Body Mass Index (BMI) outside the range (below the 5th percentile or above the 95th percentile) for height, age and weight except for children \< 2 years of age.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics: AUC0-∞ | From pre-dose until 6 hours after the start of the infusion | AUC from time zero to infinity |
| Pharmacokinetics: Cmax | From pre-dose until 6 hours after the start of the infusion | maximum measured plasma concentration |
| Pharmacokinetics: time to maximum plasma concentration (Tmax) | From pre-dose until 6 hours after the start of the infusion | time to Cmax |
| Pharmacokinetics: drug clearance (CL) | From pre-dose until 6 hours after the start of the infusion | total body clearance |
| Pharmacokinetics: t1/2 | From pre-dose until 6 hours after the start of the infusion | elimination half- life |
| Pharmacokinetics: Cmin | From pre-dose until 6 hours after the start of the infusion | minimum plasma concentration |
| Pharmacokinetics: Vss | From pre-dose until 6 hours after the start of the infusion | Volume of distribution |
| Safety and tolerability: AEs/SAEs | From assent / consent until day 7 safety follow up call | a composite measure of the number and types of AEs/SAEs encountered and relationship to time of dosing |
| Safety and tolerability: clinical safety laboratory results | From assent / consent until day 7 safety follow up call | A composite measure of multiple laboratory results assessing the clinical significance of any changes from baseline |
| Safety and tolerability: vital signs | From assent / consent until day 7 safety follow up call | A composite of multiple vital sign measurements, assessing the clinical significance of any changes from baseline |
| Safety and tolerability: ECGs | From assent / consent until day 7 safety follow up call | A composite of multiple ECG measurements, assessing the clinical significance of any changes from baseline |
Countries
United States
Outcome results
None listed